Description
A triple agonist of GLP-1, GIP, and glucagon receptors (LY3437943). Retatrutide has demonstrated unprecedented weight loss (~24% in 48 weeks in humans) by combining the effects of GLP-1/GIP (insulin secretion, appetite suppression) with glucagon’s increase of energy expenditure[23][24]. 5 mg vials are for initial testing. In obese rodent studies, retatrutide drastically improves glucose tolerance, induces fat oxidation, and even reduces liver fat and fibrosis due to its glucagon activity.
10 mg kit. At this dose, retatrutide leads to sustained high GLP-1/GIP levels plus mild glucagon receptor activation, which synergistically produce weight loss and metabolic enhancement. Researchers also examine its impact on NAFLD/NASH, as triple agonists often cause rapid fat depletion from the liver.




Reviews
There are no reviews yet.